The purpose of this article is to describe the strategies for de-escalated adjuvant therapies in early-stage breast cancer, including radiation omission, accelerated partial breast irradiation, and the role of endocrine therapy for very low-risk hormone receptor-positive (HR+) breast cancer. The gene discussed is NR4A1; the disease is breast cancer.